Gamma hydroxybutyrate is associated with a disproportionate burden of harm despite low overall population prevalence of use.

Medicinal cannabis is generally well tolerated, but the science related to its potential adverse effects is in its infancy.

Involving patients in the clinical decision-making process is integral to providing individualised care and is promoted as a hallmark of good clinical practice.

There is a great deal of interest in the potential symptomatic benefits of medicinal cannabis for developmental disorders.